Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Carcinoma, Basal Cell 3Basal Cell Nevus Syndrome 3Chondrosarcoma 1

Interventions

Gemcitabine 2Docetaxel 2tanespimycin 1resiquimod 1poly ICLC 1durvalumab 1capivasertib 1Thalidomide 1Taxes 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiotherapy, Conformal 1Radiosurgery 1Quality of Life 1Pentetic Acid 1Patient Reported Outcome Measures 1Palliative Care 1Paclitaxel 1Nutritional Support 1Molecular Diagnostic Techniques 1Minocycline 1Immunotherapy 1Immunologic Techniques 1Immunoglobulin G 1Imatinib Mesylate 1IPI-926 1Heparin 1Filgrastim 1Fentanyl 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chondrosarcoma × IPI-926 × Dermatologic × Clear all
NCT01609179 2012-11-14

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

Infinity Pharmaceuticals, Inc.

Phase NA Completed
9 enrolled
DermatologicSarcoma

Carcinoma, Basal Cell, Chondrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡